Trial Profile
Phase I, Open Label, Dose Escalation Study to Investigate the Tolerability and Efficacy of APO010 in Patients With Relapsed/Refractory Multiple Myeloma Selected by Drug Response Predictor (DRP)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs APO 010 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Proof of concept
- Sponsors Allarity Therapeutics; Oncology Venture
- 28 Jan 2020 Status changed from recruiting to discontinued.
- 07 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 07 Feb 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.